424 related articles for article (PubMed ID: 32972782)
1. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
2. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
Musoro JZ; Sodergren SC; Coens C; Pochesci A; Terada M; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Colorectal Dis; 2020 Dec; 22(12):2278-2287. PubMed ID: 32767619
[TBL] [Abstract][Full Text] [Related]
3. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
[TBL] [Abstract][Full Text] [Related]
4. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
Dirven L; Musoro JZ; Coens C; Reijneveld JC; Taphoorn MJB; Boele FW; Groenvold M; van den Bent MJ; Stupp R; Velikova G; Cocks K; Sprangers MAG; King MT; Flechtner HH; Bottomley A
Neuro Oncol; 2021 Aug; 23(8):1327-1336. PubMed ID: 33598685
[TBL] [Abstract][Full Text] [Related]
5. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer.
Musoro JZ; Coens C; Singer S; Tribius S; Oosting SF; Groenvold M; Simon C; Machiels JP; Grégoire V; Velikova G; Cocks K; Sprangers MAG; King MT; Bottomley A;
Head Neck; 2020 Nov; 42(11):3141-3152. PubMed ID: 32627261
[TBL] [Abstract][Full Text] [Related]
6. Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.
Musoro JZ; Coens C; Fiteni F; Katarzyna P; Cardoso F; Russell NS; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Bottomley A;
JNCI Cancer Spectr; 2019 Sep; 3(3):pkz037. PubMed ID: 32328553
[TBL] [Abstract][Full Text] [Related]
7. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
Musoro JZ; Coens C; Sprangers MAG; Brandberg Y; Groenvold M; Flechtner HH; Cocks K; Velikova G; Dirven L; Greimel E; Singer S; Pogoda K; Gamper EM; Sodergren SC; Eggermont A; Koller M; Reijneveld JC; Taphoorn MJB; King MT; Bottomley A;
Eur J Cancer; 2023 Jul; 188():171-182. PubMed ID: 37257278
[TBL] [Abstract][Full Text] [Related]
8. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
Gamper EM; Musoro JZ; Coens C; Stelmes JJ; Falato C; Groenvold M; Velikova G; Cocks K; Flechtner HH; King MT; Bottomley A;
BMC Cancer; 2021 Oct; 21(1):1083. PubMed ID: 34620124
[TBL] [Abstract][Full Text] [Related]
9. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
Koller M; Musoro JZ; Tomaszewski K; Coens C; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A
Lung Cancer; 2022 May; 167():65-72. PubMed ID: 35413526
[TBL] [Abstract][Full Text] [Related]
10. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
Kawahara T; Taira N; Shiroiwa T; Hagiwara Y; Fukuda T; Uemura Y; Mukai H
Qual Life Res; 2022 Jun; 31(6):1829-1836. PubMed ID: 34982354
[TBL] [Abstract][Full Text] [Related]
11. Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol.
Musoro ZJ; Hamel JF; Ediebah DE; Cocks K; King MT; Groenvold M; Sprangers MAG; Brandberg Y; Velikova G; Maringwa J; Flechtner HH; Bottomley A; Coens C;
BMJ Open; 2018 Jan; 8(1):e019117. PubMed ID: 29326191
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
Reni M; Braverman J; Hendifar A; Li CP; Macarulla T; Oh DY; Riess H; Tempero M; Lu B; Marcus J; Joshi N; Botteman M; Dueck AC
Ann Surg Oncol; 2021 Nov; 28(12):7545-7554. PubMed ID: 33813673
[TBL] [Abstract][Full Text] [Related]
13. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
Maringwa JT; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Vercauteren J; Cleeland CS; Flechtner H; Gotay C; Greimel E; Taphoorn MJ; Reeve BB; Koch JS; Weis J; Smit EF; van Meerbeeck JP; Bottomley A;
Support Care Cancer; 2011 Nov; 19(11):1753-60. PubMed ID: 20886240
[TBL] [Abstract][Full Text] [Related]
14. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
[TBL] [Abstract][Full Text] [Related]
15. Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.
Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Chow E
Asia Pac J Clin Oncol; 2014 Jun; 10(2):109-17. PubMed ID: 23551530
[TBL] [Abstract][Full Text] [Related]
16. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
[TBL] [Abstract][Full Text] [Related]
17. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
Sully K; Trigg A; Bonner N; Moreno-Koehler A; Trennery C; Shah N; Yucel E; Panjabi S; Cocks K
Eur J Haematol; 2019 Nov; 103(5):500-509. PubMed ID: 31444815
[TBL] [Abstract][Full Text] [Related]
18. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.
Snyder CF; Blackford AL; Sussman J; Bainbridge D; Howell D; Seow HY; Carducci MA; Wu AW
Qual Life Res; 2015 May; 24(5):1207-16. PubMed ID: 25398495
[TBL] [Abstract][Full Text] [Related]
19. International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.
Petersen MA; Aaronson NK; Conroy T; Costantini A; Giesinger JM; Hammerlid E; Holzner B; Johnson CD; Kieffer JM; van Leeuwen M; Nolte S; Ramage JK; Tomaszewski KA; Waldmann A; Young T; Zotti P; Groenvold M;
Qual Life Res; 2020 May; 29(5):1405-1417. PubMed ID: 31955374
[TBL] [Abstract][Full Text] [Related]
20. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
Maringwa J; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Reeve BB; Gotay C; Greimel E; Flechtner H; Cleeland CS; Schmucker-Von Koch J; Weis J; Van Den Bent MJ; Stupp R; Taphoorn MJ; Bottomley A;
Ann Oncol; 2011 Sep; 22(9):2107-2112. PubMed ID: 21324954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
